Synergy CHC Corp. Other Accounts Payable and Accrued Liabilities
Synergy CHC Corp. (SNYR) had Other Accounts Payable and Accrued Liabilities of $123.23 thousand as of 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Notes › Payables and Accruals
us-gaap:OtherAccountsPayableAndAccruedLiabilities · last filed 2026-05-14
- 2026-03-31: Other Accounts Payable and Accrued Liabilities $123.23K.
- 2025-12-31: Other Accounts Payable and Accrued Liabilities $150.87K.
- 2025-09-30: Other Accounts Payable and Accrued Liabilities $62.05K.
- 2025-06-30: Other Accounts Payable and Accrued Liabilities $89.87K.
| Period end | Other Accounts Payable and Accrued Liabilities |
|---|---|
| 2026-03-31 | $123.23K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $150.87K 10-Q · filed 2026-05-14 |
| 2025-09-30 | $62.05K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $89.87K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $155.89K 10-Q · filed 2025-05-15 |
| 2024-12-31 | $155.44K 10-K · filed 2026-04-01 |
| 2024-09-30 | $224.68K 10-Q · filed 2024-12-06 |
| 2023-12-31 | $154.99K 10-K · filed 2025-03-31 |
| 2015-12-31 | $371.52K 10-K · filed 2016-03-30 |
| 2015-09-30 | $190.14K 10-Q · filed 2015-11-16 |
| 2015-06-30 | $155.76K 10-Q · filed 2015-08-13 |
| 2015-03-31 | $133.13K 10-Q · filed 2015-05-15 |
| 2014-12-31 | $15.86K 10-K · filed 2016-03-30 |
| 2013-12-31 | $16.05K 10-K · filed 2015-03-31 |
| 2013-07-31 | $23.69K 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |